APEX1 and breast cancer: To the best of our knowledge, this is the first demonstration that dual targeting of redox APE1 and STAT3 in breast cancer is a more effective strategy than single inhibitors for reducing cell survival and proliferation, inducing cell death, and reducing cell aggressiveness through the decrease in cell migration and invasion.